Physician profile
Bindu Simon
NPI 1396266136
$2,494.48
in general payments reported to CMS, 2019-2025
20 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $558 · 2023: $810 · 2024: $648 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,686.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $554.32 | 2021-2023 | Lokelma, Farxiga |
| Genzyme Corporation | $259.58 | 2024 | |
| Horizon Therapeutics Plc | $247.03 | 2022-2023 | Krystexxa |
| Amgen INC. | $165.01 | 2022-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $149.49 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $121.84 | 2022 | |
| Vifor Pharma, INC. | $120.92 | 2022-2023 | Veltassa |
| Idorsia Pharmaceuticals US INC | $119.91 | 2025 | Tryvio |
| Nxstage Medical, INC. | $117.12 | 2022-2024 | Nxstage System One, Nxstage Cartridge Express |
| Ardelyx, INC. | $106.72 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $85.26 | 2024-2025 | Jynarque |
| Baxter Healthcare | $84.64 | 2023-2024 | Renal - Pd, Renal - Acute |
| Travere Therapeutics, INC. | $73.01 | 2024 | |
| Fresenius USA Marketing, INC. | $53.08 | 2023 | Crit-Line |
| Opko Pharmaceuticals, LLC | $48.68 | 2023 | Rayaldee |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $47.51 | 2023-2025 | Voraxaze |
| Abbott Laboratories | $41.52 | 2023 | Eterna, Prodigy |
| Mallinckrodt Hospital Products INC. | $38.26 | 2023 | Terlivaz |
| Glaxosmithkline, LLC. | $37.38 | 2023 | |
| Calliditas Therapeutics US INC. | $23.20 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.